Evidence map›Paper›PMID 39477391›Full record

ArticleIn vivo (Athens, Greece)

Long-term Effect of the HCV Elimination With Direct-acting Antivirals on the Progression of Gastroesophageal Varices.

Yukihisa Yuri, Takashi Nishimura, Naoto Ikeda, Tomoyuki Takashima, Nobuhiro Aizawa, Taro Kimura, Kohei Yoshihara, Ryota Yoshioka, Shoki Kawata, Yuta Kawase and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yukihisa YuriDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.
Takashi NishimuraDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.
Naoto IkedaDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.
Tomoyuki TakashimaDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.
Nobuhiro AizawaDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.
Taro KimuraDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.
Kohei YoshiharaDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.
Ryota YoshiokaDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.
Shoki KawataDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.
Yuta KawaseDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.
Ryota NakanoDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.
Hideyuki ShiomiDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.
Shinya FukunishiDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.
Shinichiro ShinzakiDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.
Hirayuki EnomotoDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan enomoto@hyo-med.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimGastroesophageal varices (GEV) hemorrhage is a serious complication that can lead to unfavorable outcomes in cirrhotic patients. However, the clinical impact of HCV elimination [sustained viral response (SVR)] by direct-acting antivirals (DAAs), particularly on the long-term effects on the endoscopic findings of GEV have not been sufficiently evaluated. This study aimed to investigate whether HCV elimination with DAA treatment suppresses the progression of GEV. PATIENTS AND

methodsThe clinical courses of the endoscopic findings of GEV were retrospectively compared between patients without an SVR (non-SVR group: n=71) and those who achieved an SVR with DAAs (DAA-SVR group: n=38).

resultsAt 1, 3, 5, and 7 years, the cumulative GEV progression rates were 8.7%, 32.8%, 45.6%, and 66.2%, respectively. At 3 years, the cumulative GEV progression rate in the DAA-SVR group was similar to that in the non-SVR group. Beyond 3 years, cases with GEV progression were found in the non-SVR group, but not in the DAA-SVR group. At 7 years, the cumulative GEV progression rate in the DAA-SVR group was significantly lower than that in the non-SVR group (p<0.05, log-rank test). Variceal hemorrhage occurred in eight patients in the non-SVR group, while no bleeding events were observed in the DAA-SVR group during the observational period [8/71 (11.3%) vs. 0/38 (0.0%), p<0.05].

conclusionDAA treatment suppresses the progression of GEV over the long term.

Indexed as

Antiviral AgentsDisease ProgressionEsophageal and Gastric VaricesHepacivirusSustained Virologic ResponseAdultAgedFemaleGastrointestinal HemorrhageHepatitis CHepatitis C, ChronicHumansLiver CirrhosisMaleMiddle AgedRetrospective StudiesAntiviral Agentsdirect-acting antiviralsgastroesophageal varicesHepatitis C virusliver cirrhosissustained viral response

Identifiers

PMID39477391
PMCPMC11535916

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.